Anemia is a major complication in patients with chronic kidney disease, as the 
damaged kidney is unable to produce enough erythropoietin. Peginesatide 
(formerly known as Hematide™) is a synthetic, peptide-based 
erythropoiesis-stimulating agent linked to polyethylene glycol. Based on 
extensive preclinical and clinical data substantiating the efficacy and safety 
of this agent, it was approved in the U.S. in March 2012 for the treatment of 
anemia due to chronic kidney disease in adult patients on dialysis. Peginesatide 
(Omontys®) was launched in the U.S. in April 2012.